Search results for " treatment outcome"

showing 10 items of 288 documents

The HCV Sicily Network: A web-based model for the management of HCV chronic liver diseases

2016

Epidemiological studies report that in Sicily reside about 30,000 citizens with a diagnosis of chronic hepatitis due to HCV. The availability of direct antiviral action (DAA) is a real therapeutic breakthrough, but the high cost of the therapeutic regimes limits their use and forced the National Health System to establish clinical priority for the treatment.The HCV Sicily Network is a web-based model of best medical practice, which was designed to improve the management and the treatment of HCV chronic hepatitis and cirrhosis. The network includes 41 centers and 84 gastroenterologists or infectivologists connected by a web platform that recorder the diagnosis and the clinic priority for the…

Antiviral AgentMaleInternetHepaciviruHepatitis C virusInterferon-alphaDirect antiviral agent drugs (DAA); Hepatitis C virus; Web-based network; Pharmacology (medical)HepacivirusHepatitis C ChronicMiddle AgedWeb-based network; Hepatitis C virus; Direct antiviral agent drugs (DAAAntiviral AgentsCommunity NetworksTreatment OutcomeAntiviral Agents; Drug Therapy Combination; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Internet; Male; Middle Aged; Ribavirin; Sicily; Treatment Outcome; Community NetworksRibavirinHumansDirect antiviral agent drugs (DAADrug Therapy CombinationSicilyWeb-based networkHuman
researchProduct

Outcomes of aortic valve repair according to valve morphology and surgical techniques

2012

OBJECTIVES: The aim of this study was to assess the impact of aortic valve morphology and different surgical aortic valve repair techni- ques on long-term clinical outcomes. METHODS: Between February 2003 and May 2010, 216 patients with aortic insufficiency underwent aortic valve repair in our institu- tion. Ages ranged between 26 and 82 years (mean 53 ± 15 years). Aortic valve dysfunctions, according to functional classification, were: type I in 55 patients (25.5%), type II in 126 (58.3%) and type III in 35 (16.2%). Sixty-six patients (27.7%) had a bicuspid valve. Aortic valve repair techniques included sub-commissural plasty in 138 patients, plication in 84, free-edge reinforcement in 80,…

Aortic valveMaleTime Factorsmedicine.medical_treatmentKaplan-Meier EstimateAortic valve repairRecurrenceRisk FactorsMitral valve80 and overHospital MortalityCoronary Artery BypassAortaUltrasonographyAged 80 and overTricuspid valveCalcinosisCardiac Valve AnnuloplastyMiddle AgedAortic valve repair • Bicuspid aortic valve • Tricuspid aortic valve • Aortic annulus stabilization medicine.anatomical_structureTreatment OutcomeAortic ValveReplantationcardiovascular systemCardiologyChordae TendineaeMitral ValveFemaleChordae tendineaeCardiology and Cardiovascular MedicineAdult; Aged; Aged 80 and over; Aorta; Aortic Valve; Aortic Valve Insufficiency; Blood Vessel Prosthesis Implantation; Calcinosis; Chordae Tendineae; Coronary Artery Bypass; Disease-Free Survival; Female; Hospital Mortality; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mitral Valve; Proportional Hazards Models; Recurrence; Replantation; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Ultrasonography; Cardiac Valve Annuloplasty; Suture TechniquesPulmonary and Respiratory MedicineAdultmedicine.medical_specialtyAortic Valve InsufficiencyRisk AssessmentCardiac Valve AnnuloplastyDisease-Free SurvivalBlood Vessel Prosthesis ImplantationBicuspid valveInternal medicinemedicineHumansAgedProportional Hazards ModelsMitral valve repairbusiness.industrySuture TechniquesSettore MED/23 - Chirurgia CardiacaOriginal ArticlesSurgerySurgerybusiness
researchProduct

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-…

2017

Background: \ud Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes.\ud \ud Methods: \ud In this randomised, double-blind, placebo-controlled trial, adults with prediabetes and a body-mass index of at least 30 kg/m2, or at least 27 kg/m2 with comorbidities, were randomised 2:1, using a telephone or web-based system, to once-daily subcutaneous liraglutide 3·0 mg or matched placebo, as an adjunct to a reduced-…

Blood GlucoseMaleEXENATIDEType 2 diabetes030204 cardiovascular system & hematologyBody Mass Indexlaw.inventionPlacebosImpaired glucose toleranceMELLITUS3.0 MG0302 clinical medicineRandomized controlled trialGlucagon-Like Peptide 1lawPREVENTION PROGRAM OUTCOMESPrediabetesPREVENTION PROGRAM OUTCOMES; IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE; CLINICAL-TRIAL; OBESE SUBJECTS; 3.0 MG; REGRESSION; EXENATIDE; MELLITUSSubcutaneousMedicine (all)General MedicineMiddle AgedAdult; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus Type 2; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Injections Subcutaneous; Liraglutide; Male; Middle Aged; Obesity; Placebos; Prediabetic State; Risk Reduction Behavior; Treatment Outcome; Weight Loss3. Good healthTreatment OutcomeFemaleLIFE-STYLEType 2OBESE SUBJECTSmedicine.drugAdultmedicine.medical_specialtyInjections Subcutaneous030209 endocrinology & metabolismPlaceboIncretinsGlucagon-Like Peptide-1 ReceptorInjectionsCLINICAL-TRIALPrediabetic State03 medical and health sciencesIMPAIRED GLUCOSE-TOLERANCEDouble-Blind MethodDiabetes mellitusInternal medicineWeight LossREGRESSIONDiabetes MellitusmedicineHumansHypoglycemic AgentsObesityLiraglutidebusiness.industryBody WeightLiraglutidemedicine.diseaseClinical trialEndocrinologyDiabetes Mellitus Type 2Human medicinebusinessRisk Reduction Behavior[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyThe Lancet
researchProduct

Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospe…

2019

Abstract Aims According to cardiovascular outcome trials, some sodium‐glucose contransporter‐2 inhibitors (SGLT2i) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are recommended for secondary cardiovascular prevention in type 2 diabetes (T2D). In this real‐world study, we compared the simultaneous reductions in HbA1c, body weight and systolic blood pressure after initiation of dapagliflozin or GLP‐1RA as second or a more advanced line of therapy. Materials and methods DARWIN‐T2D was a retrospective multi‐centre study conducted at diabetes specialist clinics in Italy that compared T2D patients who initiated dapagliflozin or GLP‐1RA (exenatide once weekly or liraglutide). Data were c…

Blood GlucoseMaleGlycated Hemoglobin AEndocrinology Diabetes and MetabolismBlood PressureType 2 diabetes030204 cardiovascular system & hematologySettore MED/13 - Endocrinologiachemistry.chemical_compound0302 clinical medicineEndocrinologyGlucosidesClinical endpointMedicineDapagliflozinGLP-1 analogueMiddle AgedTreatment Outcomeglycaemic controlantidiabetic drug; dapagliflozin; GLP-1 analogue; glycaemic control; observational studyCombinationOriginal ArticleDrug Therapy CombinationFemaleType 2medicine.drugAdultmedicine.medical_specialty030209 endocrinology & metabolismGlucagon-Like Peptide-1 Receptor03 medical and health sciencesDrug TherapyGLP-1 analogue; antidiabetic drug; dapagliflozin; glycaemic control; observational studyGLP‐1 analogueInternal medicineDiabetes mellitusInternal MedicineDiabetes MellitusHumansHypoglycemic AgentsBenzhydryl CompoundsAgedRetrospective StudiesGlycated Hemoglobinantidiabetic drugantidiabetic drug; dapagliflozin; GLP-1 analogue; glycaemic control; observational study; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus Type 2; Diabetic Angiopathies; Drug Therapy Combination; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycated Hemoglobin A; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Retrospective Studies; Treatment Outcomebusiness.industryLiraglutideBody WeightRetrospective cohort studyOriginal ArticlesdapagliflozinLiraglutidemedicine.diseaseBlood pressureDiabetes Mellitus Type 2chemistryPropensity score matchingExenatideobservational studybusinessAntidiabetic drug dapagliflozin GLP-1 analogue glycaemic control observational studyDiabetic Angiopathies
researchProduct

POSTPRANDIAL HYPERGLYCEMIA IS A DETERMINANT OF PLATELET ACTIVATION IN EARLY 2 DIABETES MELLITUS

2010

BACKGROUND: Chronic hyperglycemia is a major contributor to in vivo platelet activation in diabetes mellitus. OBJECTIVES: To evaluate the effects of acarbose, an alpha-glucosidase inhibitor, on platelet activation and its determinants in newly diagnosed type 2 diabetic patients. METHODS: Forty-eight subjects (26 males, aged 61 +/- 8 years) with early type 2 diabetes (baseline hemoglobin A(1c) < or = 7% and no previous hypoglycemic treatment) were randomly assigned to acarbose up to 100 mg three times a day or placebo, and evaluated every 4 weeks for 20 weeks. The main outcome measures were urinary 11-dehydro-thromboxane (TX)B(2) (marker of in vivo platelet activation) and 8-iso-prostaglandi…

Blood GlucoseMaleTime FactorsSettore MED/09 - Medicina InternaDinoprostpostprandial hyperglycemia; platelet activationMedicineEnzyme InhibitorsSettore MED/49 - Scienze Tecniche Dietetiche Applicatepostprandial hyperglycemiaAcarboseplateletHemoglobin AHematologyMiddle AgedPostprandial PeriodP-SelectinPostprandialTreatment OutcomeC-Reactive ProteinItalyFemaleBiological MarkersAcarboseType 2medicine.drugacarbose platelet activation postprandial hyperglycemia type 2 diabetes mellitusmedicine.medical_specialtySettore BIO/14 - FARMACOLOGIAUrinary systemCD40 LigandGlycosylatedArginineExcretionBlood Glucose; Time Factors; Lipid Peroxidation; Middle Aged; Hemoglobin A Glycosylated; Postprandial Period; Diabetes Mellitus Type 2; Enzyme Inhibitors; Hypoglycemic Agents; P-Selectin; Platelet Activation; Aged; CD40 Ligand; Treatment Outcome; Male; Female; Thromboxane B2; Dinoprost; Italy; Arginine; Acarbose; Double-Blind Method; Humans; Biological Markers; Hyperglycemia; alpha-Glucosidases; C-Reactive ProteinDouble-Blind MethodInternal medicineDiabetes mellitusDiabetes MellitusHypoglycemic AgentsHumansGlycoside Hydrolase InhibitorsPlatelet activationGlycemicAgedGlycated Hemoglobinbusiness.industryType 2 Diabetes Mellitusalpha-Glucosidasesmedicine.diseasePlatelet ActivationThromboxane B2EndocrinologyDiabetes Mellitus Type 2HyperglycemiaLipid PeroxidationbusinessBiomarkers
researchProduct

First case in Italy of acquired resistance to oseltamivir in an immunocompromised patient with influenza A/H1N1v infection

2010

A pandemic influenza A/H1N1v strain with the neuraminidase H274Y mutation was detected in nasal secretions of a 2-year-old leukemic patient with influenza-like illness after 18 days of treatment with oseltamivir. At baseline, no drug-resistant virus was found, while 4 days after treatment initiation a mix- ture of wild-type and mutated virus was detected. After treatment interruption, the wild type influenza virus re-emerged and became prevalent in nasal secretions after a few days, suggesting the lower fitness of the mutated virus strain. The patient slowly improved concurrently with a decrease in virus load, which resulted negative 42 days after diagnosis. No other drug-resistant influenz…

Bodily SecretionsvirusesResistanceDrug ResistanceSettore MED/42 - Igiene Generale E Applicatamedicine.disease_causePandemic H1N1v Oseltamivir Resistancechemistry.chemical_compoundInfluenza A Virus H1N1 SubtypePandemicInfluenza A virusInfluenza A VirusViralChildViral LoadTreatment OutcomeInfectious DiseasesItalyChild PreschoolRNA ViralFemaleViral diseaseViral loadH1N1vSequence AnalysisH1N1v; Oseltamivir; Pandemic; Resistance; Amino Acid Substitution; Antiviral Agents; Bodily Secretions; Child Preschool; Female; Humans; Immunocompromised Host; Influenza A Virus H1N1 Subtype; Influenza Human; Italy; Molecular Sequence Data; Mutation Missense; Neuraminidase; Nose; Oseltamivir; RNA Viral; Sequence Analysis DNA; Treatment Outcome; Viral Load; Viral Proteins; Withholding Treatment; Drug Resistance Viral; Virology; Infectious DiseasesHumanOseltamivirMolecular Sequence DataMutation MissenseNeuraminidaseBiologyNoseAntiviral AgentsVirusresistanceImmunocompromised HostViral ProteinsOseltamivirVirologyDrug Resistance ViralInfluenza HumanmedicineHumansH1N1 SubtypePreschoolInfluenza-like illnessPandemicSequence Analysis DNADNAVirologyInfluenzaInfluenza; A/H1N1v; Oseltamivir; resistancechemistryAmino Acid SubstitutionWithholding TreatmentMutationbiology.proteinRNAA/H1N1vMissenseNeuraminidase
researchProduct

CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis.

2014

SummaryCancer stem cells drive tumor formation and metastasis, but how they acquire metastatic traits is not well understood. Here, we show that all colorectal cancer stem cells (CR-CSCs) express CD44v6, which is required for their migration and generation of metastatic tumors. CD44v6 expression is low in primary tumors but demarcated clonogenic CR-CSC populations. Cytokines hepatocyte growth factor (HGF), osteopontin (OPN), and stromal-derived factor 1α (SDF-1), secreted from tumor associated cells, increase CD44v6 expression in CR-CSCs by activating the Wnt/β-catenin pathway, which promotes migration and metastasis. CD44v6− progenitor cells do not give rise to metastatic lesions but, when…

CA15-3Animals; Biomarkers Tumor; Bone Morphogenetic Proteins; Carcinogenesis; Colonic Neoplasms; Fibroblasts; Humans; Hyaluronan Receptors; Mice SCID; Neoplasm Metastasis; Neoplasm Proteins; Neoplastic Stem Cells; Phosphatidylinositol 3-Kinases; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Signal Transduction; Treatment Outcome; Wnt Proteins; Cellular Reprogramming; Molecular Medicine; Genetics; Cell BiologyCarcinogenesisWnt ProteinMice SCIDmedicine.disease_causeAnimals; Antigens CD44; Biomarkers Tumor; Bone Morphogenetic Proteins; Carcinogenesis; Colonic Neoplasms; Fibroblasts; Humans; Mice SCID; Neoplasm Metastasis; Neoplasm Proteins; Neoplastic Stem Cells; Phosphatidylinositol 3-Kinases; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Signal Transduction; Treatment Outcome; Wnt Proteins; Cellular ReprogrammingMetastasisMicePhosphatidylinositol 3-KinasesCD44Neoplasm MetastasisCarcinogenesiPhosphoinositide-3 Kinase InhibitorsColonic NeoplasmTumorbiologyProto-Oncogene Proteins c-metCellular ReprogrammingPrognosisAntigens CD44Neoplasm ProteinsNeoplasm MetastasiAnimals; Antigens CD44; Biomarkers Tumor; Bone Morphogenetic Proteins; Carcinogenesis; Colonic Neoplasms; Fibroblasts; Humans; Mice SCID; Neoplasm Metastasis; Neoplasm Proteins; Neoplastic Stem Cells; Phosphatidylinositol 3-Kinases; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Signal Transduction; Treatment Outcome; Wnt Proteins; Cellular Reprogramming; Cell Biology; Molecular Medicine; GeneticsHyaluronan ReceptorsTreatment OutcomeBone Morphogenetic ProteinsColonic NeoplasmsNeoplastic Stem CellsFibroblastMolecular MedicineHepatocyte growth factorStem cellHumanmedicine.drugSignal TransductionPrognosiProtein Kinase InhibitorSCIDNeoplasm ProteinCancer stem cellSettore MED/04 - PATOLOGIA GENERALEmedicineGeneticsBiomarkers TumorAnimalsHumansAntigensProgenitor cellProtein Kinase InhibitorsSettore MED/04 - Patologia GeneraleAnimalBone Morphogenetic Proteincancer metastasisCD44Cell BiologyFibroblastsmedicine.diseaseWnt ProteinsSettore MED/18 - Chirurgia GeneraleImmunologyCancer researchbiology.proteinNeoplastic Stem CellPhosphatidylinositol 3-KinaseCarcinogenesisBiomarkersCell stem cell
researchProduct

Intensity-modulated extended-field chemoradiation plus simultaneous integrated boost in the pre-operative treatment of locally advanced cervical canc…

2015

Objective: To investigate the feasibility and determine the recommended pre-operative intensity-modulated radiotherapy (IMRT) dose of extended-field chemoradiation along with simultaneous integrated boost (SIB) dose escalation. Methods: A radiation dose of 40Gy over 4 weeks, 2Gy/fraction, was delivered to the tumour and the lymphatic drainage (planning target volume, PTV3), which encompassed a volume larger than standard (common iliac lymphatic area up to its apex, in front of the L3 vertebra), concurrently with chemotherapy (cisplatin and 5-fluorouracil). Radiation dose was escalated to the pelvis (PTV2) and to the macroscopic disease (PTV1) with the SIB-IMRT strategy. Three dose levels we…

Chemoradiotherapy; Dose Fractionation; Feasibility Studies; Female; Humans; Middle Aged; Neoplasm Staging; Preoperative Period; Prospective Studies; Radiotherapy Dosage; Radiotherapy Planning Computer-Assisted; Radiotherapy Intensity-Modulated; Treatment Outcome; Uterine Cervical Neoplasms; Radiology Nuclear Medicine and Imaging; Medicine (all)Uterine Cervical NeoplasmRadiology Nuclear Medicine and Imagingcervical cancermedicine.medical_treatmentUterine Cervical NeoplasmsMedicineHumansProspective StudiesProspective cohort studyDose FractionationSettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIANeoplasm StagingCervical cancerCisplatinChemotherapyFull Paperbusiness.industryMedicine (all)Radiotherapy Planning Computer-AssistedDose fractionationRadiotherapy DosageGeneral MedicineChemoradiotherapyMiddle Agedmedicine.diseaseRadiation therapyFeasibility StudieProspective StudieLymphatic systemTreatment OutcomePreoperative PeriodFeasibility StudiesFemaleDose Fractionation RadiationRadiotherapy Intensity-ModulatedbusinessNuclear medicineChemoradiotherapymedicine.drugHumanThe British journal of radiology
researchProduct

High-flow nasal therapy versus noninvasive ventilation in COPD patients with mild-to-moderate hypercapnic acute respiratory failure: study protocol f…

2019

Background Noninvasive ventilation (NIV) is indicated to treat respiratory acidosis due to exacerbation of chronic obstructive pulmonary disease (COPD). Recent nonrandomized studies also demonstrated some physiological effects of high-flow nasal therapy (HFNT) in COPD patients. We designed a prospective, unblinded, multicenter, randomized controlled trial to assess the noninferiority of HFNT compared to NIV with respect to the reduction of arterial partial pressure of carbon dioxide (PaCO2) in patients with hypercapnic acute respiratory failure with mild-to-moderate respiratory acidosis. Methods We will enroll adult patients with acute hypercapnic respiratory failure, as defined by arterial…

Chronic ObstructiveTime FactorsExacerbationRespiratory ratemedicine.medical_treatmentMedicine (miscellaneous)Equivalence Trials as TopicAcute respiratory failurelaw.inventionPulmonary DiseaseHypercapnia03 medical and health sciencesPulmonary Disease Chronic ObstructiveStudy Protocol0302 clinical medicineAcute respiratory failure; Carbon dioxide; Chronic obstructive pulmonary disease; Emergency department; High-flow oxygen therapy through nasal cannula; Intensive care unit; Noninvasive ventilation; Acute Disease; Equivalence Trials as Topic; Humans; Hypercapnia; Italy; Lung; Multicenter Studies as Topic; Oxygen Inhalation Therapy; Prospective Studies; Pulmonary Disease Chronic Obstructive; Respiratory Insufficiency; Time Factors; Treatment Outcome; Noninvasive VentilationRandomized controlled triallawHigh-flow oxygen therapy through nasal cannulamedicineHumansMulticenter Studies as TopicPharmacology (medical)Intensive care unit030212 general & internal medicineProspective StudiesLungTidal volumeMechanical ventilationCOPDlcsh:R5-920business.industryEmergency departmentChronic obstructive pulmonary diseaseOxygen Inhalation Therapymedicine.diseaseIntensive care unitRespiratory acidosisTreatment OutcomeItalyCarbon dioxideAnesthesiaAcute DiseasebusinessRespiratory Insufficiencylcsh:Medicine (General)Acute respiratory failure; Carbon dioxide; Chronic obstructive pulmonary disease; Emergency department; High-flow oxygen therapy through nasal cannula; Intensive care unit; Noninvasive ventilationNoninvasive ventilation030217 neurology & neurosurgeryTrials
researchProduct

Excimer laser technology in percutaneous coronary interventions: Cardiovascular laser society's position paper

2022

Excimer Laser Coronary Atherectomy (ELCA) is a well-established therapy that emerged for the treatment of peripheral vascular atherosclerosis in the late 1980s, at a time when catheters and materials were rudimentary and associated with the most serious complications. Refinements in catheter technology and the introduction of improved laser techniques have led to their effective use for the treatment of a wide spectrum of complex coronary lesions, such as thrombotic lesions, severe calcific lesions, non-crossable or non-expandable lesions, chronic occlusions, and stent under-expansion. The gradual introduction of high-energy strategies combined with the contrast infusion technique has enabl…

Chronic occlusionAtherectomy CoronaryTechnologyAtherectomySevere calcific lesionChronic occlusions; ELCA; Laser angioplasty; Severe calcific lesions; Stent under-expansion; Thrombotic lesions; Coronary Angiography; Humans; Lasers Excimer; Technology; Treatment Outcome; Atherectomy Coronary; Percutaneous Coronary InterventionLasersCoronaryThrombotic lesionCoronary AngiographyChronic occlusionsExcimerTreatment OutcomePercutaneous Coronary InterventionStent under-expansionSevere calcific lesionsHumansLaser angioplastyLasers ExcimerELCACardiology and Cardiovascular MedicineThrombotic lesionsHumanInternational Journal of Cardiology
researchProduct